{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:46:48Z","timestamp":1792673208246,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tracli.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:56:32Z","timestamp":1789602992000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infectious risks of transfusion: A 10-year look back and perspectives"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-9517","authenticated-orcid":false,"given":"Evan M.","family":"Bloch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Drews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-9685","authenticated-orcid":false,"given":"Jeremy W.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2026.09.004_bib0935","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tmrv.2020.02.001","article-title":"Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016","volume":"34","author":"Dodd","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2026.09.004_bib0940","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.09.004_bib0945","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tracli.2022.07.001","article-title":"Deferral of men who have sex with men from blood donation: Policy and change","volume":"29","author":"Bloch","year":"2022","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2026.09.004_bib0950","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/trf.12951","article-title":"Risk factors for retrovirus and hepatitis virus infections in accepted blood donors","volume":"55","author":"Custer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib0955","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/trf.13247","article-title":"Blood donor deferral for men who have sex with men: the Blood Donation Rules Opinion Study (Blood DROPS)","volume":"55","author":"Custer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib0960","doi-asserted-by":"crossref","first-page":"e0170364","DOI":"10.1371\/journal.pone.0170364","article-title":"Attitudes, perceptions and knowledge among men who have sex with men towards the blood donation deferral policy in Israel","volume":"12","author":"Levy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tracli.2026.09.004_bib0965","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/vox.12623","article-title":"Donor deferral policies for men who have sex with men: past, present and future","volume":"113","author":"Goldman","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib0970","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/trf.16250","article-title":"HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men","volume":"61","author":"Steele","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib0975","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/vox.12826","article-title":"Changing the deferral for men who have sex with men - an improved model to estimate HIV residual risk","volume":"114","author":"Davison","year":"2019","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib0980","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/trf.16753","article-title":"HIV incidence and compliance with deferral criteria over three progressively shorter time deferrals for men who have sex with men in Canada","volume":"62","author":"Caffrey","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib0985","unstructured":"FDA. Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human (Accessed: September 4 2025)."},{"key":"10.1016\/j.tracli.2026.09.004_bib0990","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tracli.2026.09.004_bib0995","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1000","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.tracli.2026.09.004_bib1005","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1371\/journal.pctr.0020027","article-title":"Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial","volume":"2","author":"Peterson","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.tracli.2026.09.004_bib1010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciw365","article-title":"Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology","volume":"63","author":"de Souza","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1015","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1097\/QAD.0000000000001577","article-title":"The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion","volume":"31","author":"Donnell","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.tracli.2026.09.004_bib1020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/tme.12957","article-title":"Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: A qualitative study","volume":"33","author":"van den Berg","year":"2023","journal-title":"Transfus Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2020006890","article-title":"HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern","volume":"136","author":"Custer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.09.004_bib1030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tracli.2018.07.001","article-title":"Pathogen inactivation\/reduction technologies for platelet transfusion: Where do we stand?","volume":"25","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/vox.70199","article-title":"Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017-2024","volume":"121","author":"Laperche","year":"2026","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib1040","unstructured":"US Food and Drug Administration. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. December 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance (Accessed: July 22, 2026."},{"key":"10.1016\/j.tracli.2026.09.004_bib1045","first-page":"Cd009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","volume":"7","author":"Estcourt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tracli.2026.09.004_bib1050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tracli.2026.02.005","article-title":"Impact of the amotosalen\/UVA process to reduce pathogens in platelet concentrates on transfusion efficiency in cardiac surgery","volume":"33","author":"Bouali","year":"2026","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1055","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/ALN.0000000000005716","article-title":"Transfusion of amustaline\/glutathione pathogen-reduced red blood cells in cardiac surgery: a randomized Phase 3 clinical trial","volume":"143","author":"Sekela","year":"2025","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tracli.2026.09.004_bib1060","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/trf.16112","article-title":"Extension of platelet shelf life with an improved bacterial testing algorithm","volume":"60","author":"Ramirez-Arcos","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1065","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/trf.16000","article-title":"Performance profile of an updated safety measure rapid assay for bacteria in platelets","volume":"60","author":"Vallejo","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.transci.2018.12.011","article-title":"Physiology of cold-stored platelets","volume":"58","author":"Getz","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2026.09.004_bib1075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tmrv.2020.08.003","article-title":"Cold-stored platelets: review of studies in humans","volume":"34","author":"Mack","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2026.09.004_bib1080","doi-asserted-by":"crossref","first-page":"2188969","DOI":"10.1080\/09537104.2023.2188969","article-title":"Cold stored platelets in the management of bleeding: is it about bioenergetics?","volume":"34","author":"George","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.tracli.2026.09.004_bib1085","unstructured":"US Food and Drug Administration. Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical. June 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/alternative-procedures-manufacture-cold-stored-platelets-intended-treatment-active-bleeding-when (Accessed: July 22, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/ALN.0000000000003550","article-title":"A pilot trial of platelets stored cold versus at room temperature for complex cardiothoracic surgery","volume":"133","author":"Strandenes","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tracli.2026.09.004_bib1095","unstructured":"ClinicalTrials.gov. CHIlled Platelet Study \u201cCHIPS\u201d (CHIPS) (NCT04834414). https:\/\/clinicaltrials.gov\/study\/NCT04834414 (Accessed: July 22, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/17407745221126423","article-title":"Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study","volume":"20","author":"Zantek","year":"2023","journal-title":"Clin Trials"},{"key":"10.1016\/j.tracli.2026.09.004_bib1105","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.13328","article-title":"Cold and room-temperature platelets in cardiac surgery: The CHIPS Randomized Clinical Trial","author":"Spinella","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.tracli.2026.09.004_bib1110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jama.2025.23355","article-title":"Cryopreserved vs liquid-stored platelets for the treatment of surgical bleeding: The CLIP-II Randomized Noninferiority Clinical Trial","volume":"335","author":"Reade","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.tracli.2026.09.004_bib1115","doi-asserted-by":"crossref","DOI":"10.1111\/trf.70295","article-title":"Donor management implications for high-sensitivity detection of low-level malaria parasitemia in blood donor screening","author":"Charlton","year":"2026","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1120","doi-asserted-by":"crossref","first-page":"e0190424","DOI":"10.1128\/jcm.01904-24","article-title":"Improved HIV-1 RNA detection using whole blood versus plasma in antiretroviral-treated individuals","volume":"63","author":"Avelino-Silva","year":"2025","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1125","unstructured":"W.H. Organization. Global status report on blood safety and availability 2016. 2017. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4ae2fe88-7f9d-4da0-9dac-69ab3e3494b2\/content (Accessed: 2026-08-09."},{"key":"10.1016\/j.tracli.2026.09.004_bib1130","unstructured":"W.H. Organization. Global status report on blood safety and availability 2025. [2026]. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/aa36bd85-6947-4097-adf6-f734922c8026\/content (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1135","doi-asserted-by":"crossref","first-page":"e0009222","DOI":"10.1128\/jcm.00092-22","article-title":"Proceedings of the Clinical Microbiology Open 2018 and 2019 - A discussion about emerging trends, challenges, and the future of clinical microbiology","volume":"60","author":"Doern","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1140","doi-asserted-by":"crossref","first-page":"1775715","DOI":"10.3389\/fpubh.2026.1775715","article-title":"Scientific and technological mapping of big data architectures in healthcare","volume":"14","author":"Santos","year":"2026","journal-title":"Front Public Health"},{"key":"10.1016\/j.tracli.2026.09.004_bib1145","doi-asserted-by":"crossref","first-page":"150769","DOI":"10.1016\/j.tmrv.2023.150769","article-title":"Leveraging donor populations to study the epidemiology and pathogenesis of transfusion-transmitted and emerging infectious diseases","volume":"37","author":"Bloch","year":"2023","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2026.09.004_bib1150","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.rser.2017.09.087","article-title":"Could energy hamper future developments in information and communication technologies (ICT) and knowledge engineering?","volume":"82","author":"Aktas","year":"2018","journal-title":"Renewable and Sustainable Energy Reviews"},{"key":"10.1016\/j.tracli.2026.09.004_bib1155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-016-0323-y","article-title":"Making sense of big data in health research: Towards an EU action plan","volume":"8","author":"Auffray","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1160","unstructured":"K.A. Bowers N. AAAS policy forum: AI breakthroughs, challenges and calls to action. 2025. (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.aei9754","article-title":"Does AI work for us, or do we work for AI?","volume":"393","author":"Wu","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.tracli.2026.09.004_bib1170","unstructured":"W.H. Organization. Regional strategic preparedness and response plan: Regional strategic, preparedness and response plan in the Democratic Republic of Congo. 2025. https:\/\/www.afro.who.int\/sites\/default\/files\/2025-09\/Regional_SPRP_EVD_29%20September%202025_final.pdf (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1175","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature02759","article-title":"The challenge of emerging and re-emerging infectious diseases","volume":"430","author":"Morens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2026.09.004_bib1180","unstructured":"W.H. Organization. Global spending on health: emerging from the pandemic. 2024. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/6a22149b-17d5-4afb-a89b-14a3e8c12442\/content (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1185","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/vox.70162","article-title":"A congress report of the new Emerging Pathogens and Parasitology Subgroup within the ISBT Working Party on Transfusion-Transmitted Infectious Diseases","volume":"121","author":"Drews","year":"2026","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib1190","unstructured":"U. Nations. UN Global Pulse, \u201cHorizon Scan User Manual: A step-by-step guide\u201d. Anticipation Capability, November 2022. 2022. https:\/\/www.unglobalpulse.org\/document\/horizon-scan-manual-a-step-by-step-guide\/."},{"key":"10.1016\/j.tracli.2026.09.004_bib1195","unstructured":"World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. March 11, 2020. https:\/\/www.who.int\/news-room\/speeches\/item\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (Accessed: July 22, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1200","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/trf.16511","article-title":"Minipool testing for SARS-CoV-2 RNA in United States blood donors","volume":"61","author":"Bakkour","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1205","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood.2020008230","article-title":"No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation","volume":"136","author":"Cappy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2026.09.004_bib1210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tracli.2020.11.002","article-title":"The impact of COVID-19 pandemic on blood supplies and transfusion services in Eastern Mediterranean Region","volume":"28","author":"Al-Riyami","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1215","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(20)30186-1","article-title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","volume":"7","author":"Stanworth","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1220","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/trf.17116","article-title":"Blood conservation strategies at United States hospitals during the COVID-19 pandemic: Findings from a multi-institutional analysis - International Society of Blood Transfusion survey","volume":"62","author":"Jacobs","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1225","doi-asserted-by":"crossref","first-page":"103297","DOI":"10.1016\/j.transci.2021.103297","article-title":"Blood shortages and changes to massive transfusion protocols: Survey of hospital practices during the COVID-19 pandemic","volume":"61","author":"Jacobs","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2026.09.004_bib1230","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2026.09.004_bib1235","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1240","doi-asserted-by":"crossref","first-page":"e2250647","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tracli.2026.09.004_bib1245","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) | CBER-Regulated Biologics. https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/coronavirus-covid-19-cber-regulated-biologics (Accessed: July 22, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1250","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tracli.2026.09.004_bib1255","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","article-title":"Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions","volume":"9","author":"Marshall","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1260","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. https:\/\/www.who.int\/publications\/i\/item\/9789240091672(Accessed: July 21, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-050223-111239","article-title":"Global elimination of hepatitis C virus","volume":"76","author":"Fleurence","year":"2025","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1270","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1275","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S2468-1253(21)00137-0","article-title":"Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study","volume":"6","author":"Olafsson","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1280","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/ciz956","article-title":"Three years of progress toward achieving hepatitis C elimination in the Country of Georgia, April 2015-March 2018","volume":"71","author":"Tsertsvadze","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1285","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMra1202018","article-title":"Human babesiosis","volume":"366","author":"Vannier","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1290","first-page":"1447","article-title":"The global emergence of human babesiosis","volume":"10","author":"Kumar","year":"2021","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.tracli.2026.09.004_bib1295","article-title":"Preventing transfusion-transmitted babesiosis","volume":"10","author":"Bloch","year":"2021","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.tracli.2026.09.004_bib1300","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/trf.13618","article-title":"Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay","volume":"56","author":"Levin","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1305","doi-asserted-by":"crossref","DOI":"10.1111\/j.1537-2995.2009.02430.x","article-title":"Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007","author":"Johnson","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1310","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1537-2995.2012.03948.x","article-title":"Babesia microti seroprevalence in Minnesota blood donors","volume":"53","author":"Tonnetti","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1315","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1056\/NEJMoa1600897","article-title":"Screening for Babesia microti in the U.S. Blood Supply","volume":"375","author":"Moritz","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1320","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/trf.17244","article-title":"Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange","volume":"63","author":"Costa","year":"2023","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1325","unstructured":"FDA. Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria. 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transfusion-transmitted-malaria-0 (Accessed: September 2 2025)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1330","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/trf.17612","article-title":"A novel mitigation strategy for the prevention of transfusion-transmitted malaria","volume":"64","author":"Tonnetti","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1335","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3201\/eid2207.151990","article-title":"A literature review of Zika Virus","volume":"22","author":"Plourde","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1340","unstructured":"WHO. WHO Director-General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barr\u00e9 syndrome. 2016. http:\/\/www.who.int\/mediacentre\/news\/statements\/2016\/emergency-committee-zika-microcephaly\/en\/ (Accessed: 24 April 2019)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15585\/mmwr.mm6503e2","article-title":"Possible association between Zika virus infection and microcephaly - Brazil, 2015","volume":"65","author":"Schuler-Faccini","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1350","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1355","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika virus infection in pregnant women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1360","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/trf.13681","article-title":"Probable transfusion-transmitted Zika virus in Brazil","volume":"56","author":"Barjas-Castro","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1365","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMc1607262","article-title":"Evidence for transmission of Zika virus by platelet transfusion","volume":"375","author":"Motta","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1370","doi-asserted-by":"crossref","first-page":"774","DOI":"10.15585\/mmwr.mm6530e1","article-title":"Update: ongoing Zika virus transmission - Puerto Rico, November 1, 2015-July 7, 2016","volume":"65","author":"Adams","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1375","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/trf.14029","article-title":"First Zika-positive donations in the continental United States","volume":"57","author":"Galel","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1380","unstructured":"FDA. Food and Drug Administration (FDA). Recommendations for Donor Screening Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus: Guidance for Industry. In: F.a.D.A. U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research editor. Silver Spring, MD: 2016."},{"key":"10.1016\/j.tracli.2026.09.004_bib1385","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3201\/eid2305.161631","article-title":"Zika virus infection and prolonged viremia in whole-blood specimens","volume":"23","author":"Mansuy","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1390","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1111\/trf.15484","article-title":"Acute Zika virus infection in an asymptomatic blood donor at the onset of the Puerto Rico epidemic","volume":"59","author":"Saa","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1395","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/M18-2238","article-title":"Screening the blood supply for Zika virus in the 50 U.S. States and Puerto Rico: a cost-effectiveness analysis","volume":"170","author":"Russell","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1400","unstructured":"FDA. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components: Guidance for Industry. In: H.a.H. Services editor: 2018."},{"key":"10.1016\/j.tracli.2026.09.004_bib1405","unstructured":"US Food and Drug Administration. Recommendations to reduce the risk of transfusion-transmitted malaria: guidance for industry. December 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transfusion-transmitted-malaria (Accessed: July 21, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1410","unstructured":"US Food and Drug Administration. Information for blood establishments regarding FDA's determination that Zika virus is no longer a relevant transfusion-transmitted infection. May 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/blood-blood-products\/information-blood-establishments-regarding-fdas-determination-zika-virus-no-longer-relevant (Accessed: July 21, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1415","unstructured":"US Food and Drug Administration. Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components. May 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt (Accessed: July 21, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1420","unstructured":"I.C.o.T.o. Viruses. The Master Species List: A spreadsheet of current taxonomy. 2025 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1425","unstructured":"ViralZone. Orthoflavivirus. 2026. https:\/\/viralzone.expasy.org\/24 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1430","unstructured":"W.H. Organization. Dengue. 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1435","series-title":"Control of communicable diseases manual","year":"2024"},{"key":"10.1016\/j.tracli.2026.09.004_bib1440","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.15.2400515","article-title":"Description and comparison of national surveillance systems and response measures for Aedes-borne diseases in France, Italy and Portugal: a benchmarking study, 2023","volume":"30","author":"Fotakis","year":"2025","journal-title":"Euro Surveill"},{"key":"10.1016\/j.tracli.2026.09.004_bib1445","doi-asserted-by":"crossref","DOI":"10.3390\/v17020224","article-title":"Detecting arboviruses through screening asymptomatic blood donors in Rio de Janeiro\/Brazil suring a Dengue outbreak","volume":"17","author":"Ribeiro","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.tracli.2026.09.004_bib1450","first-page":"267","article-title":"Prevalence of Chikungunya, Dengue and Zika viruses in blood donors: a systematic literature review and meta-analysis","volume":"20","author":"Gim\u00e9nez-Richarte","year":"2022","journal-title":"Blood Transfus"},{"key":"10.1016\/j.tracli.2026.09.004_bib1455","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/infdis\/jiv326","article-title":"III. Transfusion-transmitted dengue and associated clinical symptoms during the 2012 epidemic in Brazil","volume":"213","author":"Sabino","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1460","doi-asserted-by":"crossref","first-page":"1380129","DOI":"10.3389\/fmed.2024.1380129","article-title":"High prevalence of dengue, Zika, and chikungunya viruses in blood donors during a dengue outbreak and an endemic period in Colombia","volume":"11","author":"C\u00e1ceres Munar","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.tracli.2026.09.004_bib1465","unstructured":"ViralZone. Alphavirus. 2026. https:\/\/viralzone.expasy.org\/625 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1470","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-016648","article-title":"The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease","volume":"9","author":"de Roo","year":"2024","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.tracli.2026.09.004_bib1475","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/tme.13119","article-title":"A prospective, multi-centric study on the prevalence of dengue, zika and chikungunya in asymptomatic blood donors from different geographical regions of Brazil","volume":"35","author":"Langhi","year":"2025","journal-title":"Transfus Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1480","unstructured":"AABB. Chikungunya. 2024. https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/eid\/chikungunya-virus.pdf?sfvrsn=fce34c85_5."},{"key":"10.1016\/j.tracli.2026.09.004_bib1485","unstructured":"ViralZone. Peribunyaviridae. 2026. https:\/\/viralzone.expasy.org\/82."},{"key":"10.1016\/j.tracli.2026.09.004_bib1490","doi-asserted-by":"crossref","first-page":"769","DOI":"10.15585\/mmwr.mm7335e1","article-title":"Oropouche virus disease among U.S. travelers - United States, 2024","volume":"73","author":"Morrison","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1495","doi-asserted-by":"crossref","first-page":"103871","DOI":"10.1016\/j.eclinm.2026.103871","article-title":"Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications","volume":"95","author":"Subissi","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tracli.2026.09.004_bib1500","unstructured":"U.C.f.D.C.a. Prevention. Clinical overview of Oropouche virus disease. 2025. https:\/\/www.cdc.gov\/oropouche\/hcp\/clinical-overview\/index.html (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1505","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3201\/eid1306.061114","article-title":"Reemergence of Oropouche fever, northern Brazil","volume":"13","author":"Azevedo","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1510","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14121272","article-title":"Preclinical models of Oropouche virus infection and disease","volume":"14","author":"Morley","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.tracli.2026.09.004_bib1515","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/infdis\/jiag088","article-title":"Molecular and serological evidence of Oropouche virus circulation in asymptomatic blood donors during the 2023-2024 outbreak in Manaus, Brazil","volume":"234","author":"Milani","year":"2026","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1520","doi-asserted-by":"crossref","first-page":"108516","DOI":"10.1016\/j.ijid.2026.108516","article-title":"The risk of transfusion-transmitted infection: First evidence of Oropouche virus detection in an asymptomatic blood donor in Southeastern Brazil","volume":"167","author":"Alvarez","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1525","doi-asserted-by":"crossref","DOI":"10.3390\/v17060738","article-title":"Oropouche virus (OROV) and breastfeeding safety: Analysis of related orthobunyaviruses for mother-infant vertical transmission in breast milk","volume":"17","author":"Schwartz","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.tracli.2026.09.004_bib1530","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/OGX.0000000000001403","article-title":"Oropouche infection: Concerns for the obstetric patient","volume":"80","author":"Damron","year":"2025","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.tracli.2026.09.004_bib1535","unstructured":"AABB. Oropouche virus \u2013 Interim fact sheet. 2024. https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/eid\/oropouche-virus-interim-fact-sheet.pdf?sfvrsn=c15a5efe_5 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1540","article-title":"An international study on emerging arboviral infections and blood safety","author":"Rajendra","year":"2026","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1545","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/trf.17921","article-title":"Evaluation of assays for nucleic acid testing for the prevention of chikungunya and dengue virus transmission by blood transfusion","volume":"64","author":"Gallian","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1550","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/tmi.13863","article-title":"Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: A systematic review and meta-analysis","volume":"28","author":"Gim\u00e9nez-Richarte","year":"2023","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.tracli.2026.09.004_bib1555","unstructured":"E.C.f.D.P.a. Control. Deferral criteria and testing strategies for dengue virus in blood donors returning from affected areas \u2013 survey results. 2025. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Dengue-survey-SoHO-2025.pdf."},{"key":"10.1016\/j.tracli.2026.09.004_bib1560","unstructured":"OneBlood. OneBlood strategy to protect the blood supply from mosquito-borne (Arbovirus) disease. 2016. https:\/\/www.floridahealth.gov\/wp-content\/uploads\/2025\/07\/policy-42-2.pdf (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1565","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/vox.70185","article-title":"Assessing dengue outbreak risks to blood donation safety, beyond significant outbreak areas in Australia","volume":"121","author":"Viennet","year":"2026","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib1570","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/trf.18326","article-title":"West Nile Virus positivity amongst Canadian blood donors and effectiveness of off-season screening","volume":"65","author":"Charlton","year":"2025","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1575","doi-asserted-by":"crossref","first-page":"627","DOI":"10.15585\/mmwr.mm6524e2","article-title":"Screening of blood donations for Zika virus infection - Puerto Rico, April 3-June 11, 2016","volume":"65","author":"Kuehnert","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1580","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1086\/514285","article-title":"Human infection due to Ebola virus, subtype C\u00f4te d\u2019Ivoire: clinical and biologic presentation","volume":"179","author":"Formenty","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1585","doi-asserted-by":"crossref","first-page":"e1013579","DOI":"10.1371\/journal.ppat.1013579","article-title":"Mucosal Ta\u00ef Forest virus infection causes disease in ferrets","volume":"21","author":"Fletcher","year":"2025","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tracli.2026.09.004_bib1590","doi-asserted-by":"crossref","first-page":"101236","DOI":"10.1016\/j.onehlt.2025.101236","article-title":"Global distribution and genetic diversity of orthoebolaviruses: Mapping and evolutionary analysis","volume":"21","author":"Cheng","year":"2025","journal-title":"One Health"},{"key":"10.1016\/j.tracli.2026.09.004_bib1595","unstructured":"B.B. Practice. Ebola disease. 2026. https:\/\/bestpractice.bmj.com\/topics\/en-us\/1210\/aetiology (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1600","unstructured":"U.C.f.D.C.a. Prevention. Ebola disease basics. 2026. https:\/\/www.cdc.gov\/ebola\/about\/index.html (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1605","unstructured":"U.C.f.D.C.a. Prevention. Signs and symptoms of Ebola disease. 2024. https:\/\/www.cdc.gov\/ebola\/signs-symptoms\/index.html (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1610","unstructured":"W.H. Organization. Disease Outbreak News; Bundibugyo Virus Disease, Democratic Republic of the Congo (The) and Uganda. 2026. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON602 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1615","unstructured":"AABB. Ebola virus. 2024. https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/eid\/ebola-virus.pdf?sfvrsn=f95e3128_3 (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1620","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(26)00414-7","article-title":"A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness","author":"Kuppalli","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1625","unstructured":"U.S.D.o.H.a.H.S.F.a.D. Administration, C.f.B.E.a. Research. Recommendations for assessment of blood donor eligibility, donor deferral and blood product management in response to an Ebola disease outbreak: Guidance for industry. 2026. https:\/\/www.fda.gov\/media\/94902\/download."},{"key":"10.1016\/j.tracli.2026.09.004_bib1630","doi-asserted-by":"crossref","first-page":"e0004676","DOI":"10.1371\/journal.pntd.0004676","article-title":"Potential impact of sexual transmission on Ebola virus epidemiology: Sierra Leone as a case study","volume":"10","author":"Abbate","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1635","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.celrep.2018.01.008","article-title":"Active Ebola virus replication and heterogeneous evolutionary rates in EVD survivors","volume":"22","author":"Whitmer","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1640","unstructured":"E.C.f.D.P.a. Control. Risk of Bundibugyo virus transmission through substances of human origin in the European Union\/European Economic Area (EU\/EEA). 2026. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/risk-bundibugyo-virus-transmission-through-substances-human-origin-european (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1645","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000499121","article-title":"Blood donor screening for hepatitis E virus in the European Union","volume":"46","author":"Boland","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tracli.2026.09.004_bib1650","doi-asserted-by":"crossref","first-page":"17086","DOI":"10.1038\/nrdp.2017.86","article-title":"Hepatitis E virus infection","volume":"3","author":"Kamar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tracli.2026.09.004_bib1655","first-page":"110","article-title":"Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives","volume":"21","author":"Laperche","year":"2023","journal-title":"Blood Transfus"},{"key":"10.1016\/j.tracli.2026.09.004_bib1660","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3201\/eid2809.220487","article-title":"Fulminant transfusion-associated hepatitis E virus infection despite screening, England, 2016-2020","volume":"28","author":"Harvala","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1665","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/trf.13976","article-title":"Hepatitis E risks: pigs or blood-that is the question","volume":"57","author":"Tedder","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1670","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/trf.13994","article-title":"Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression","volume":"57","author":"Satake","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1675","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.10.1800386","article-title":"Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening","volume":"24","author":"Harvala","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.tracli.2026.09.004_bib1680","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/gutjnl-2023-330602","article-title":"Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients","volume":"73","author":"Thornton","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.tracli.2026.09.004_bib1685","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3201\/eid2801.211466","article-title":"Effect of hepatitis E virus RNA universal blood donor screening, Catalonia, Spain, 2017\u20132020","volume":"28","author":"Bes","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1690","unstructured":"Haut Conseil de la sant\u00e9 publique. S\u00e9curisation des produits et \u00e9l\u00e9ments issus du corps humain vis-\u00e0-vis du virus de l\u2019h\u00e9patite E. April 20, 2023. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=1326 (Accessed: July 21, 2026)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1695","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/trf.17696","article-title":"Universal nucleic acid donor screening revealed epidemiological features of hepatitis E and prevented transfusion-transmitted infection in Japan","volume":"64","author":"Tanaka","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1700","doi-asserted-by":"crossref","first-page":"150835","DOI":"10.1016\/j.tmrv.2024.150835","article-title":"Hepatitis E VIrus in the United States and Canada: is it time to consider blood donation screening?","volume":"38","author":"Bienz","year":"2024","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2026.09.004_bib1705","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3201\/eid2612.191482","article-title":"Risk for hepatitis E virus transmission by solvent\/detergent-treated plasma","volume":"26","author":"Gallian","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tracli.2026.09.004_bib1710","unstructured":"ViralZone. Deltaretrovirus. 2026. https:\/\/viralzone.expasy.org\/91?outline=all_by_species (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1715","doi-asserted-by":"crossref","first-page":"611","DOI":"10.17269\/s41997-024-00886-6","article-title":"Prevalence of human T-cell lymphotropic virus-1\/2 in Canada over 33\u00a0years: A unique contribution of blood donors to public health surveillance","volume":"115","author":"O\u2019Brien","year":"2024","journal-title":"Can J Public Health"},{"key":"10.1016\/j.tracli.2026.09.004_bib1720","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/vox.12722","article-title":"Human T-cell lymphotropic virus: A simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada","volume":"113","author":"O\u2019Brien","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib1725","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/trf.17279","article-title":"Low risk of human T-lymphotropic virus infection in U.S. blood donors; Is it time to consider a one-time selective testing approach?","volume":"63","author":"Crowder","year":"2023","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1730","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/trf.12105","article-title":"Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction","volume":"53","author":"Hewitt","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1735","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/trf.18464","article-title":"An international survey of blood operator human T-cell lymphotropic virus-1\/2 testing practices","volume":"65","author":"Drews","year":"2025","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1740","unstructured":"O\u2019Brien S. Surveillance report 2025. https:\/\/professionaleducation.blood.ca\/en\/transfusion\/publications\/surveillance-report (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1745","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1111\/trf.16696","article-title":"Prevention of transfusion-transmitted syphilis by blood operators: How much is enough when transfusion-transmission has not been identified for decades?","volume":"61","author":"Drews","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1750","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/trf.17393","article-title":"Monitoring syphilis serology in blood donors: Is there utility as a surrogate marker of early transfusion transmissible infection behavioral risk?","volume":"63","author":"O\u2019Brien","year":"2023","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1755","unstructured":"A.R.C. Lifeblood. Donation testing. 2026. https:\/\/www.lifeblood.com.au\/health-professionals\/testing\/donation (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1760","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/trf.15815","article-title":"Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program","volume":"60","author":"Bloch","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1765","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/trf.16262","article-title":"Bacterial contamination of blood products in Africa","volume":"61","author":"Ahmad","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1770","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/trf.14949","article-title":"Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century","volume":"59","author":"Weimer","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1775","doi-asserted-by":"crossref","first-page":"482","DOI":"10.7326\/M20-0203","article-title":"Blood transfusion safety in low-resourced countries: aspiring to a higher standard","volume":"173","author":"Bloch","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2026.09.004_bib1780","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/trf.14544","article-title":"Quest for the holy grail: pathogen reduction in low-income countries","volume":"58","author":"Tobian","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1785","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(16)00581-X","article-title":"Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial","volume":"387","author":"Allain","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2026.09.004_bib1790","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13063-022-06137-8","article-title":"The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial","volume":"23","author":"Kasirye","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.tracli.2026.09.004_bib1795","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/trf.14374","article-title":"Funding blood safety in the 21st century","volume":"58","author":"Ifland","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2026.09.004_bib1800","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10111430","article-title":"Ticks, human babesiosis and climate change","volume":"10","author":"Gray","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.tracli.2026.09.004_bib1805","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDpha2600131","article-title":"Emergence of Babesiosis in Nova Scotia, Canada","volume":"5","author":"Drews","year":"2026","journal-title":"NEJM Evid"},{"key":"10.1016\/j.tracli.2026.09.004_bib1810","doi-asserted-by":"crossref","first-page":"eaeb7613","DOI":"10.1126\/sciadv.aeb7613","article-title":"Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease","volume":"12","author":"Hannaoui","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.tracli.2026.09.004_bib1815","unstructured":"U.o.M. Center for Infectious Disease Research and Policy (CIDRAP). Chronic Wasting Disease Spillover Preparedness and Response: Charting an Uncertain Future. 2025. https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/CWD%20Report%202025_0.pdf (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1820","doi-asserted-by":"crossref","first-page":"eaec2657","DOI":"10.1126\/science.aec2657","article-title":"Generative design of bacteriophages with genome language models","volume":"393","author":"King","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.tracli.2026.09.004_bib1825","doi-asserted-by":"crossref","first-page":"1879718","DOI":"10.3389\/fcimb.2026.1879718","article-title":"Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases","volume":"16","author":"Zhang","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tracli.2026.09.004_bib1830","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s42256-024-00926-3","article-title":"Toward a framework for risk mitigation of potential misuse of artificial intelligence in biomedical research","volume":"6","author":"Trotsyuk","year":"2024","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.tracli.2026.09.004_bib1835","unstructured":"H. L. Two more people cured of HIV after stem cell transplants, offering more clues to long-term remission. 2026. https:\/\/www.aidsmap.com\/news\/jul-2026\/two-more-people-cured-hiv-after-stem-cell-transplants-offering-more-clues-long-term (Accessed: 2026-08-09)."},{"key":"10.1016\/j.tracli.2026.09.004_bib1840","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s12325-026-03591-7","article-title":"Indirect treatment comparison of the efficacy of long-acting injectable cabotegravir compared with lenacapavir for HIV pre-exposure prophylaxis","volume":"43","author":"Hawkins","year":"2026","journal-title":"Adv Ther"},{"key":"10.1016\/j.tracli.2026.09.004_bib1845","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/COH.0000000000000919","article-title":"HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges","volume":"20","author":"Elliott","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.tracli.2026.09.004_bib1850","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.ekir.2025.02.002","article-title":"Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: A case series","volume":"10","author":"Efe","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.tracli.2026.09.004_bib1855","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/vox.12230","article-title":"Presence of medication taken by blood donors in plasma for transfusion","volume":"108","author":"van Tilborgh-de Jong","year":"2015","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2026.09.004_bib1860","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200154","article-title":"Severe neuroinvasive West Nile virus in association with anti-CD20 monotherapy for multiple sclerosis","volume":"10","author":"Thebault","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782026001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:11:50Z","timestamp":1792671110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782026001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":186,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1246782026001291"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2026.09.004","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious risks of transfusion: A 10-year look back and perspectives","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 francophone de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}